A1 Refereed original research article in a scientific journal

Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice



Authors: Mia Ståhle, Johanna M.U. Silvola, Sanna Hellberg, Margreet de Vries, Paul H. A. Quax, Jeffrey Kroon, Petteri Rinne, Alwin de Jong, Heidi Liljenbäck, Nina Savisto, Anna Wickman, Erik S.G. Stroes, Seppo Ylä-Herttuala, Pekka Saukko, Tommy Abrahamsson, Knut Pettersson, Juhani Knuuti, Anne Roivainen, Antti Saraste,

Publisher: Elsevier Inc

Publication year: 2020

Journal: JACC: Basic to Translational Science

Journal name in source: JACC: Basic to Translational Science

Volume: 5

Issue: 4

First page : 360

Last page: 373

ISSN: 2452-302X

eISSN: 2452-302X

DOI: https://doi.org/10.1016/j.jacbts.2020.01.008

Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/47290852


Abstract

This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.


Last updated on 2024-26-11 at 20:17